Table 2.
Chronic Disease Score (CDS) and CDS-ID Components for Patients with or without Surgical Site Infection (SSI)
| CDS-ID Category | Components | SSI (n=66) n (%) |
No SSI (n=375) n (%) |
P | Weighting Scheme | |
|---|---|---|---|---|---|---|
| CDS | CDS-ID | |||||
| Heart disease | a) Anti-coagulants | 29 (44%) | 170 (45%) | 0.83 | 3 | -- |
| b) Cardiac agents (includes ACE inhibitors) | 9 (14%) | 47 (13%) | 0.80 | 4 | -- | |
| c) Loop diuretics | 36 (55%) | 121(32%) | 0.26 | 5 | -- | |
| Respiratory illness | a) Isoproterenol | 0 | 0 | -- | One class = 2 | 1.38, any class |
| b) Beta-adrenergic* | 9 (14%) | 34 (9%) | 0.25 | |||
| c) Xanthine products | 0 | 0 | -- | Two or more classes = 3 | ||
| d) Bronchodialators and mucolytics | 1(2%) | 5 (1%) | -- | |||
| e) Epinephrine | 0 | 4 (1%) | -- | |||
| Asthma, rheumatism | Glucocorticoids | 58 (88%) | 336 (90%) | 0.68 | 3 | -- |
| Rheumatoid arthritis | Gold salts | 1(2%) | 1(0.3%) | -- | 3 | -- |
| Cancer | Antineoplastics | 33 (50%) | 188 (50%) | 0.98 | 3 | 1.07 |
| Parkinson’s | L-Dopa | 0 | 1 (0.3%) | -- | 3 | -- |
| Hypertension | a) Antihypertensives and calcium channel blockers (excludes ACE inhibitors) | 62 (94%) | 349 (93%) | 0.80 | 2 | -- |
| b) Beta-blockers and diuretics | 13 (20%) | 68 (18%) | 0.76 | 1 | -- | |
| Diabetes | Insulin and oral hypoglycemic | 50 (76%) | 276 (74%) | 0.71 | 2 | 1.57 |
| Epilepsy | Anticonvulsants | 14 (21%) | 62 (17%) | 0.35 | 2 | -- |
| Asthma, rhinitis | Cromolyn | 1 (2%) | 0 | -- | 2 | -- |
| Ulcers | Cimetidine | 27 (41%) | 120 (32%) | 0.16 | 1 | 1.83 |
| Glaucoma | Opthalmic miotics | 2 (3%) | 0 | -- | 1 | -- |
| Gout | Uric acid agents | 8 (12%) | 2 (0.5%) | 0.65 | 1 | -- |
| High cholesterol | Cholesterol lower agents | 11 (17%) | 43 (12%) | 0.23 | 1 | -- |
| Tuberculosis | Antitubercular agents | 0 | 0 | -- | 1 | -- |
| HIV | Antiretroviral agents | 1 (2%) | 6 (2%) | -- | -- | -- |
| Renal | Calcitrol, calcium acetate, hematopoetic agents | 8 (12%) | 55 (15%) | 0.60 | -- | 3.13 |
| Narcotic use | Opiod agonitsts, narcotic antagonists | 4 (6%) | 5 (1%) | 0.01 | -- | -- |
| Acne | a) Anticane tretinoin | 0 | 0 | -- | 1, either class | -- |
| b) Topical macrolides | 0 | 0 | -- | -- | ||
| Migraines | Ergot derivatives | 0 | 0 | -- | 1 | -- |